Shopping Cart 0
Cart Subtotal
USD 0

Cytokinetics Inc (CYTK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Cytokinetics Inc (Cytokinetics) is a late stage biopharmaceutical company, which discovers, develops, and commercializes muscle activators for the treatment of diseases associated with reduced muscle performance. The company's pipeline encompasses omecamtiv mecarbil, a novel cardiac myosin activator in Phase 3 for heart failure; and reldesemtiv, a next-generation fast skeletal muscle troponin activator in Phase 2 for the treatment of spinal muscular atrophy; chronic obstructive pulmonary disease; and in Phase 1b for frailty. It is also investigating reldesemtiv for amyotrophic lateral sclerosis. It has licensing agreements with Amgen and Astellas for advancing its drug candidates. Cytokinetics is headquartered in South San Francisco, California, the US.

Cytokinetics Inc (CYTK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cytokinetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deal Details 11

Licensing Agreements 11

Cytokinetics Enters Into Licensing Agreement With Astellas Pharma For CK-2127107 11

Astellas Pharma Expands Licensing Agreement with Cytokinetics 13

Equity Offering 15

Cytokinetics Plans to Raise Funds through Public Offering of Securities 15

Cytokinetics Prices Public Offering of Shares for USD75 Million 16

Cytokinetics to Raise up to USD40 Million in Public Offering of Shares 17

Cytokinetics Raises USD10 Million in Private Placement of Shares 18

Cytokinetics Completes Public Offering Of Shares For USD 40.3 Million 19

Cytokinetics Completes Public Offering Of Shares For USD 5 Million 21

Cytokinetics Completes Public Offering Of Common Stock And Warrants For USD 42.5 Million 22

Cytokinetics Completes Public Offering Of Preferred Stock And Warrants For USD 17.5 Million 24

Cytokinetics Inc-Key Competitors 26

Cytokinetics Inc-Key Employees 27

Cytokinetics Inc-Locations And Subsidiaries 28

Head Office 28

Recent Developments 29

Financial Announcements 29

Nov 01, 2018: Cytokinetics reports third quarter 2018 financial results 29

Jul 26, 2018: Cytokinetics Reports Second Quarter 2018 Financial Results 31

Apr 26, 2018: Cytokinetics Reports First Quarter 2018 Financial Results 34

Feb 15, 2018: Cytokinetics Reports Fourth Quarter 2017 Financial Results 36

Oct 26, 2017: Cytokinetics Reports Third Quarter 2017 Financial Results 38

Aug 02, 2017: Cytokinetics Reports Second Quarter 2017 Financial Results 40

Apr 27, 2017: Cytokinetics Reports First Quarter 2017 Financial Results 42

Feb 16, 2017: Cytokinetics Reports Fourth Quarter 2016 Financial Results 44

Corporate Communications 47

Feb 12, 2018: Cytokinetics Appoints Robert Califf, M.D., to Board of Directors 47

Product News 48

Nov 30, 2017: New Publication Shows Respiratory Decline Correlated With Disease Progression in People Living With ALS 48

Product Approvals 49

May 15, 2017: Cytokinetics Announces Orphan Drug Designation for CK-2127107 for the Treatment of Spinal Muscular Atrophy 49

Clinical Trials 50

Apr 24, 2018: Cytokinetics Announces Presentation of Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy at the 2018 Annual Cure SMA Conference 50

Feb 21, 2018: Phase 2 Clinical Trial Results for CK-2127107 Expected in Second Quarter of 2018 51

Jan 03, 2018: Cytokinetics Provides on CK-2127107 52

Dec 11, 2017: Cytokinetics Publishes Clinical Trial Data for CK-2127107 53

Nov 30, 2017: New Publication Summarizes Phase 1 Studies Of CK-2127107 Showing Tolerability And Amplification Of Skeletal Muscle Response To Nerve Activation 54

Jul 27, 2017: Cytokinetics Announces Start of FORTITUDE-ALS, a Phase 2 Clinical Trial of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis 56

Jul 05, 2017: Cytokinetics Announces Baseline Data From First Cohort of Phase 2 Clinical Trial of CK-2127107 in Patients With SMA 57

Mar 29, 2017: Cytokinetics Announces Start of Second Cohort in Phase 2 Clinical Trial of CK-2127107 in Patients With Spinal Muscular Atrophy 59

Mar 22, 2017: Cytokinetics Announces Preclinical Data for CK-2127107 Presented at MDA Scientific Conference 60

Appendix 61

Methodology 61

About GlobalData 61

Contact Us 61

Disclaimer 61


List Of Figure

List of Figures

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Cytokinetics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cytokinetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cytokinetics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Cytokinetics Enters Into Licensing Agreement With Astellas Pharma For CK-2127107 11

Astellas Pharma Expands Licensing Agreement with Cytokinetics 13

Cytokinetics Plans to Raise Funds through Public Offering of Securities 15

Cytokinetics Prices Public Offering of Shares for USD75 Million 16

Cytokinetics to Raise up to USD40 Million in Public Offering of Shares 17

Cytokinetics Raises USD10 Million in Private Placement of Shares 18

Cytokinetics Completes Public Offering Of Shares For USD 40.3 Million 19

Cytokinetics Completes Public Offering Of Shares For USD 5 Million 21

Cytokinetics Completes Public Offering Of Common Stock And Warrants For USD 42.5 Million 22

Cytokinetics Completes Public Offering Of Preferred Stock And Warrants For USD 17.5 Million 24

Cytokinetics Inc, Key Competitors 26

Cytokinetics Inc, Key Employees 27

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Cytokinetics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Cytokinetics Inc (Cytokinetics) is a late stage biopharmaceutical company, which discovers, develops, and commercializes muscle activators for the treatment of diseases associated with reduced muscle performance. The company's pipeline encompasses omecamtiv mecarbil, a novel cardiac myosin activator in Phase 3 for heart failure; and reldesemtiv, a next-generation fast skeletal muscle troponin activator in Phase 2 for the treatment of spinal muscular atrophy; chronic obstructive pulmonary disease; and in Phase 1b for frailty. It is also investigating reldesemtiv for amyotrophic lateral sclerosis. It has licensing agreements with Amgen and Astellas for advancing its drug candidates. Cytokinetics is headquartered in South San Francisco, California, the US.

Cytokinetics Inc (CYTK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cytokinetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deal Details 11

Licensing Agreements 11

Cytokinetics Enters Into Licensing Agreement With Astellas Pharma For CK-2127107 11

Astellas Pharma Expands Licensing Agreement with Cytokinetics 13

Equity Offering 15

Cytokinetics Plans to Raise Funds through Public Offering of Securities 15

Cytokinetics Prices Public Offering of Shares for USD75 Million 16

Cytokinetics to Raise up to USD40 Million in Public Offering of Shares 17

Cytokinetics Raises USD10 Million in Private Placement of Shares 18

Cytokinetics Completes Public Offering Of Shares For USD 40.3 Million 19

Cytokinetics Completes Public Offering Of Shares For USD 5 Million 21

Cytokinetics Completes Public Offering Of Common Stock And Warrants For USD 42.5 Million 22

Cytokinetics Completes Public Offering Of Preferred Stock And Warrants For USD 17.5 Million 24

Cytokinetics Inc-Key Competitors 26

Cytokinetics Inc-Key Employees 27

Cytokinetics Inc-Locations And Subsidiaries 28

Head Office 28

Recent Developments 29

Financial Announcements 29

Nov 01, 2018: Cytokinetics reports third quarter 2018 financial results 29

Jul 26, 2018: Cytokinetics Reports Second Quarter 2018 Financial Results 31

Apr 26, 2018: Cytokinetics Reports First Quarter 2018 Financial Results 34

Feb 15, 2018: Cytokinetics Reports Fourth Quarter 2017 Financial Results 36

Oct 26, 2017: Cytokinetics Reports Third Quarter 2017 Financial Results 38

Aug 02, 2017: Cytokinetics Reports Second Quarter 2017 Financial Results 40

Apr 27, 2017: Cytokinetics Reports First Quarter 2017 Financial Results 42

Feb 16, 2017: Cytokinetics Reports Fourth Quarter 2016 Financial Results 44

Corporate Communications 47

Feb 12, 2018: Cytokinetics Appoints Robert Califf, M.D., to Board of Directors 47

Product News 48

Nov 30, 2017: New Publication Shows Respiratory Decline Correlated With Disease Progression in People Living With ALS 48

Product Approvals 49

May 15, 2017: Cytokinetics Announces Orphan Drug Designation for CK-2127107 for the Treatment of Spinal Muscular Atrophy 49

Clinical Trials 50

Apr 24, 2018: Cytokinetics Announces Presentation of Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy at the 2018 Annual Cure SMA Conference 50

Feb 21, 2018: Phase 2 Clinical Trial Results for CK-2127107 Expected in Second Quarter of 2018 51

Jan 03, 2018: Cytokinetics Provides on CK-2127107 52

Dec 11, 2017: Cytokinetics Publishes Clinical Trial Data for CK-2127107 53

Nov 30, 2017: New Publication Summarizes Phase 1 Studies Of CK-2127107 Showing Tolerability And Amplification Of Skeletal Muscle Response To Nerve Activation 54

Jul 27, 2017: Cytokinetics Announces Start of FORTITUDE-ALS, a Phase 2 Clinical Trial of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis 56

Jul 05, 2017: Cytokinetics Announces Baseline Data From First Cohort of Phase 2 Clinical Trial of CK-2127107 in Patients With SMA 57

Mar 29, 2017: Cytokinetics Announces Start of Second Cohort in Phase 2 Clinical Trial of CK-2127107 in Patients With Spinal Muscular Atrophy 59

Mar 22, 2017: Cytokinetics Announces Preclinical Data for CK-2127107 Presented at MDA Scientific Conference 60

Appendix 61

Methodology 61

About GlobalData 61

Contact Us 61

Disclaimer 61


List Of Figure

List of Figures

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Cytokinetics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cytokinetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cytokinetics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Cytokinetics Enters Into Licensing Agreement With Astellas Pharma For CK-2127107 11

Astellas Pharma Expands Licensing Agreement with Cytokinetics 13

Cytokinetics Plans to Raise Funds through Public Offering of Securities 15

Cytokinetics Prices Public Offering of Shares for USD75 Million 16

Cytokinetics to Raise up to USD40 Million in Public Offering of Shares 17

Cytokinetics Raises USD10 Million in Private Placement of Shares 18

Cytokinetics Completes Public Offering Of Shares For USD 40.3 Million 19

Cytokinetics Completes Public Offering Of Shares For USD 5 Million 21

Cytokinetics Completes Public Offering Of Common Stock And Warrants For USD 42.5 Million 22

Cytokinetics Completes Public Offering Of Preferred Stock And Warrants For USD 17.5 Million 24

Cytokinetics Inc, Key Competitors 26

Cytokinetics Inc, Key Employees 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Cytokinetics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.